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Sporadic inclusion-body myositis (sIBM) is the most common disabling, adult-onset, inﬂammatory myopathy histologically
characterized by intense inﬂammation and vacuolar degeneration. In spite of T cell-mediated cytotoxicity and persistent, clonally
expanded and antigen-driven endomysial T cells, the disease is resistant to immunotherapies. Alemtuzumab is a humanized
monoclonal antibody that causes an immediate depletion or severe reduction of peripheral blood lymphocytes, lasting at least
6 months. We designed a proof-of-principle study to examine if one series of Alemtuzumab infusions in sIBM patients depletes
not only peripheral blood lymphocytes but also endomysial T cells and alters the natural course of the disease. Thirteen sIBM
patients with established 12-month natural history data received 0.3mg/kg/day Alemtuzumab for 4 days. The study was
powered to capture 510% increase strength 6 months after treatment. The primary end-point was disease stabilization com-
pared to natural history, assessed by bi-monthly Quantitative Muscle Strength Testing and Medical Research Council strength
measurements. Lymphocytes and T cell subsets were monitored concurrently in the blood and the repeated muscle biopsies.
Alterations in the mRNA expression of inﬂammatory, stressor and degeneration-associated molecules were examined in the
repeated biopsies. During a 12-month observation period, the patients’ total strength had declined by a mean of 14.9% based
on Quantitative Muscle Strength Testing. Six months after therapy, the overall decline was only 1.9% (P50.002), corresponding
to a 13% differential gain. Among those patients, four improved by a mean of 10% and six reported improved performance of
daily activities. The beneﬁt was more evident by the Medical Research Council scales, which demonstrated a decline in the total
scores by 13.8% during the observation period but an improvement by 11.4% (P50.001) after 6 months, reaching the level of
strength recorded 12 months earlier. Depletion of peripheral blood lymphocytes, including the naive and memory CD8+ cells,
was noted 2 weeks after treatment and persisted up to 6 months. The effector CD45RA
+CD62L
- cells, however, started to
increase 2 months after therapy and peaked by the 4th month. Repeated muscle biopsies showed reduction of CD3 lymphocytes
by a mean of 50% (P50.008), most prominent in the improved patients, and reduced mRNA expression of stressor molecules
Fas, Mip-1a and aB-crystallin; the mRNA of desmin, a regeneration-associated molecule, increased. This proof-of-principle
study provides insights into the pathogenesis of inclusion-body myositis and concludes that in sIBM one series of
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Introduction
Sporadic inclusion-body myositis (sIBM), the most common muscle
disease in patients above the age of 50, is a relentlessly progres-
sive disorder that ultimately results in severely restricted mobility,
dysphagia or even death (Dalakas, 1991, 2004; Mikol and Engel,
2004; Askanas and Engel, 2006; Needham and Mastaglia, 2007).
A combination of autoimmune and degenerative features plays a
role in the disease pathogenesis. The immunopathological hall-
marks of sIBM include prominent endomysial inﬂammation char-
acterized by a T cell-mediated and MHC-I-restricted cytotoxicity;
clonal expansion of the autoinvasive CD8+ T cells and B cells
and upregulation of cytokines, chemokines, and of co-stimulatory
molecules. The degenerative features consist of vacuolization in
ﬁbres not invaded by T cells and intracellular deposits of amyloid
and related proteins. In spite of the antigen-driven T cell response
and the strong immunopathology, immunotherapies have been
either unsuccessful or of minimal beneﬁt.
We have hypothesized that strategies targeting T cells may be
of clinical beneﬁt in sIBM if they also have the potential to
deplete or reduce some of the endomysial T cells responsible for
the T cell-mediated muscle ﬁbre injury. Alemtuzumab (Campath,
Campath-1H, or MabCAMPATH) is a recombinant DNA-derived
humanized monoclonal antibody directed against CD52, a 21–28
KD cell surface glycoprotein, predominantly expressed on the
surface of mature T lymphocytes and monocytes (Hale and
Waldmann, 2000). With conventional doses, neutrophils are not
affected, hence the reasonably good safety record of the drug
(Hale et al., 1988; Hale and Waldmann, 2000). Alemtuzumab,
approved for the treatment of T cell leukemias, induces a pro-
found and persisting—over 6 months—dose-dependent lympho-
cyte depletion (Hale et al., 1988). Monocytes and macrophages
are also depleted, but they return after 1–2 weeks due to redis-
tribution (Armstrong et al., 1998; Kirk et al., 2003). Among
non-oncologic applications, Alemtuzumab is being explored in
rheumatoid arthritis, vasculitis, multiple sclerosis and organ trans-
plantation, with very promising results (Weinblatt et al., 1995;
Flynn and Byrd, 2000; Kirk et al., 2003; Reiff, 2005; Coles
et al., 2006). Recently, a controlled study demonstrated efﬁcacy
in relapsing–remitting multiple sclerosis (The CAMMS233 Trial
Investigation, 2008).
The profound T cell depletion achieved with Alemtuzumab in
the periphery and lymphoid tissues, prompted us to examine
whether it also reduces endomysial T cells. Because B cells are
also affected, it may exert an additional beneﬁt considering the
emerging role of these cells in sIBM. If in sIBM the endomysial
T cells are myotoxic, as proposed (Dalakas, 2006; Mikol and
Engel, 2007), a reduction of these cells after 4–6 months
is expected to result in some clinical beneﬁt. Accordingly, in this
proof-of-principle study we examined the effect of Alemtuzumab
in endomysial T cells and disease progression.
Study Design and Methods
Patient selection
Patients with sIBM were selected from a pool of patients participating
in a natural history longitudinal study. These patients had been
followed in the outpatient clinic of the NIH Clinical Centre with
serial quantitative strength measurements every 6 months for up to
12–18 months, prior to enrolment in the CAMPATH study. All enrolled
patients were ambulatory and had not been taking any immuno-
modulating or immunosuppressive therapies for at least a year.
Patients were excluded if they had malignancy, coagulopathy,
low-platelet count, anaemia, cardiac insufﬁciency or thyroiditis.
The patients’ mean age was 60 (range 55–80), and the mean
disease duration from the time of diagnosis was 10 years (range
5–15). Thirteen patients were chosen (four female, nine male)
according to the order of enrolment in the natural history protocol.
The diagnosis was made on the basis of the typical clinical and
histopathological features, determined by a muscle biopsy
performed at NIH at the time of enrolment in the longitudinal
study (baseline biopsy). Prior to starting CAMPATH, all patients
had a second biopsy (pre-CAMPATH biopsy) to assess changes in
the endomysial T cells that might have occurred during the natural
history period, and examine the direct effect of CAMPATH on the
endomysial T cells based on a third (post-CAMPATH) biopsy,
as described below.
Study drug
All patients were admitted to the inpatient unit of the Clinical Centre,
NIH, under an IRB-approved protocol and after signing informed
consent. This was an investigator-initiated study, funded by the
NINDS and the Clinical Center under a ‘bench-to-bedside’ competitive
award to the principal investigator (M.C.D.). The study began after an
IND granted by the FDA to M.C.D. Infusions were conducted under
telemetry monitoring. Alemtuzumab, provided by the NIH pharmacy,
was administered by intravenous drip at a continuous rate of
0.1mg/kg/h or over a 4-h period. The infusions were repeated every
other day for a total of four doses at 0.3mg/kg/day, not exceeding
30mg/day. Patients were pre-medicated with IV methylprednisolone
250mg 2h prior to dose 1, 125mg 2h prior to dose 2 and 60mg
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and acetaminophen 650mg prior to each infusion. In addition, they
received trimethoprim/sulfamethoxazole DS (double strength) daily
three times per week, clotrimazole troche 10mg BID, and valganciclovir
450mg once daily upon initiation of treatment and up to 6 months
thereafter or until the absolute lymphocyte count (ALC) was 4500
cells/ml, whichever occurred later. Total blood counts, liver enzymes
and lymphocyte subsets were monitored daily for the ﬁrst 10 days
and weekly thereafter until CD4+ counts were equal or 4200 cells/ml
or the ALC had exceeded 500. Afterwards, lymphocyte repopulation
was assessed monthly.
Assessment of efﬁcacy
Quantitative Muscle Strength Testing (QMT), which provides a total
summed score of strength in kilograms was performed to measure
maximum voluntary isometric muscle contractions (MVIC) for grip,
wrist and elbow ﬂexion and extension, shoulder abduction, knee
extension, hip ﬂexion, and ankle dorsiﬂexion. The average of two
MVIC trials for each muscle group was analysed. Interrater and
intrarater reliability was assessed in 10 healthy volunteers with excel-
lent reliability based on intraclass correlation coefﬁcients of 0.95 and
0.93, respectively. In addition, manual muscle testing (MMT) was
administered by the same neurologist using the modiﬁed Medical
Research Council (MRC) scale, a validated 0–10 scale with excellent
interrrater reliability, to record the strength of over 30 muscle groups
bilaterally in arms and legs. All patients were tested every 6 months for
at least 12 months to obtain natural history data prior to entering
the trial. For the CAMPATH study, muscle strength was assessed at
baseline (pre-treatment) and at 2, 4, 6, 8, 10 and 12 months by the
same assessors who had also obtained the QMT and MRC scores
during the natural history period. Changes in the ability to perform
fundamental activities of daily living were assessed with a brief
questionnaire, which allowed for the subjective reporting of changes
after 6 months of therapy. The following questions were asked: (i) did
any of your symptoms improve? If so, when did you notice the
improvement and how long did it last?; (ii) what speciﬁc tasks were
you able to do after the infusions that you could not do before?;
(iii) did you consider your clinical beneﬁt sufﬁcient that you would
like to be re-treated?; (iv) on the basis of a subjective 0–10 scale,
how did you rate your overall ability to perform daily tasks prior to
therapy, 6 months after therapy and 12 months later?; and (v) did you
notice any side-effects?
Muscle biopsies
The patients underwent two open muscle biopsies, one prior
to Alemtuzumab (pre-CAMPATH) and another 6 months later
(post-CAMPATH) from the same extremity. All patients also had
a prior biopsy by us (baseline biopsy) performed at the time of
enrolment in the longitudinal study, 12–18 months prior to entering
the trial. All three biopsies were obtained under separate consents and
were processed for muscle enzyme histochemistry, immunocytochem-
istry and molecular studies. The lymphocytic inﬁltrates in all specimens
were quantiﬁed as in our previous trial (Dalakas et al., 2001). In brief,
the total number of endomysial T cells immunostained with monoclo-
nal antibodies against CD3+ and CD8+ were counted. The total
number of CD3+ and CD8+ cells and the total number of ﬁbres
were counted blindly in three randomly selected ﬁelds at 20. The
ratio of CD3+ and CD8+ cells per ﬁbre was calculated and compared
between pre- and post-treatment specimens by applying the two-
sided sample t-test. Lymphocyte count was also performed on the
baseline biopsy and compared with the pre- and post-CAMPATH
biopsies. Double immunohistochemical staining was also performed
for CD8 and CXCL-9 as previously described (Schmidt et al., 2008).
Immunologic studies in peripheral
blood lymphocytes and muscle
Lymphocyte subsets (CD3, 4, 8, 16, 20, CD45RO, CD45RA, CD52,
CD80, CD86, CD154, CD19), utilizing speciﬁc monoclonal antibodies,
were determined in the peripheral blood lymphocytes with the ﬂow
cytometry before the infusion, and every 2 months thereafter, as
previously described (Pearl, 2005). Brieﬂy, polychromatic ﬂow cytome-
try was used to ask whether post-depletional T cells (CD3+) were
predominantly CD4+ or CD8+, naı ¨ve (CD45RA+CD62L+); one of
three phenotypes associated with functional memory cells: CD45RA-
CD62L- (effector), CD45RA-CD62L+ (central) or CD45RA+CD62L-
(RA+) memory; or memory cells with potential regulatory function
(CD45RA-CD4+CD25+). To determine these phenotypes, clinical
whole blood samples were stained with the following Mab conjugates:
CD3 Cascade Blue, CD4 Cy5.5 Phycoerythrin (PE), CD8 Texas Red PE,
CD11a Cy7 allophycocyanin (APC), CD14 Cy7PE, CD25 PE, CD45RA
Cy5PE, CD45RO Cy5.5APC, CD62L ﬂuorescein isothiocyanate (FITC),
CD56 APC, and CCR7 PE. Puriﬁed antibodies to the cell-surface
markers above were obtained from BD/Pharmingen (Franklin Lakes,
NJ, USA) and conjugated to the indicated ﬂuorochromes using
standard protocols (http://drmr.com/abcon). Cascade blue, FITC,
and Texas Red PE were obtained from Molecular Probes (Eugene,
OR, USA). Phycoerythrin and APC were obtained from ProZyme
(San Leandro, CA, USA). Cy5, Cy5.5, and Cy7 were obtained from
Amersham Life Sciences (Pittsburgh, PA, USA). Compensation was set
using the ﬂuorescence minus one method for all ﬂuorochromes. Data
were collected on a modiﬁed FACSDiVa (Becton–Dickinson, Franklin
Lakes, NJ, USA) or a modiﬁed LSRII (Beckton–Dickinson) and
analysed with FlowJo software (Tree Star, San Carlos, CA, USA).
Quantitative immunocytochemistry and PCR methodology were
applied in the muscle biopsy specimens before and after therapy
to determine changes in the mRNA of the following cells and
inﬂammatory mediators: CD3, CD8,CD68, CD28, ICOS, ICOS-L,
CD52,CD80,IL1b, TGF-b,IFN-, TNF-a, IL6, CXCL9, CCL4,CCL3
and MHC-I. In brief, quantitative (real-time) PCR was performed
on an Opticon 2 DNA engine (MJ research/Applied Biosystems),
using speciﬁc primers with 6-carboxy-ﬂuorescein (FAM)-labelled
probes (Applied Biosystems, Foster City, CA, USA) and following
the standard cycle protocol and instructions given by the supplier.
Target mRNA-expression was quantiﬁed using the c(t) method
in relation to expression of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) mRNA as housekeeping gene. These inﬂamma-
tory markers were correlated with the mRNA of amyloid and
degeneration/regeneration-associated molecules including APP,
aB crystalin, NCAM, desmin and Ubiquitin, as previously described
(Schmidt et al., 2008).
Sample size, outcome measures and
power analysis
Clinical changes were evaluated on the basis of the total muscle
strength scores obtained at baseline (pre-treatment) to scores obtained
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clinical improvement was based on the difference in the total muscle
strength scores from three sequential time periods; 12 months natural
history (pre-treatment, baseline, period), 6 months after CAMPATH
(treatment period) and 6 months without treatment after completion
of CAMPATH (post-treatment period). The percentage of change in
the summed muscle strength scores obtained from each of the three
periods was compared using a repeated measures analysis of variance
(ANOVA). The ANOVA results were used to determine how the treat-
ment periods differed from the baseline measurements. All data were
checked for sphericity assumptions and Tukey’s Least Signiﬁcant
Difference procedure was used for the post hoc analyses. A change
in the muscle strength at 6 months by 510% was considered an
improvement. Based on our previous assessments of muscle strength
in inclusion-body myositis patients (Dalakas et al., 1997, 2001) and a
0.12 (or 12%) standard deviation of difference, a power analysis of a
two-sided paired t-test, 13 patients were needed to provide 80%
power to detect a change by 10% at 6 months (test signiﬁcance
level, a 0.050 with a two-sided t-test). Power analysis was not per-
formed for detecting changes in disease progression, as the percentage
of strength decline was not known at the time the protocol began.
Results
Change in muscle strength
The summed total strength measured by QMT in all patients
declined by a mean of 14.9% during a 12-month observational
period that immediately preceded the inclusion in the CAMPATH
trial (Fig. 1). In contrast, after 6 months of CAMPATH, the total
strength score had declined only by 1.9% from baseline corre-
sponding to a mean of 13% differential gain. Among those
patients, four (31%) had a mean strength gain by 10%
(4–19%), which translates to a mean of 10kg added force.
Among all patients, bilateral wrist ﬂexion and extension accounted
for the four largest percent increases of 425% each. The right
quadriceps improved by 14.4% for all patients while the left and
right hip ﬂexion improved by 3.4 and 5.6%, respectively. Follow-
up evaluations at month 12 (6 additional months after the primary
end-point, and without further treatment), showed a decline in
strength by a mean of 11.6% (P50.01) indicating that the rever-
sal of disease progression, observed during the ﬁrst 6 months of
therapy, could not be maintained without re-treatment (Fig. 1).
The QMT measurements were reinforced with the MRC data.
A mean of 13.8% decline in the strength of all patients was noted
during a 24 month natural history period (P50.001) and a 9.1%
decline during the 12-month period before therapy (P50.09).
After 6 months of CAMPATH, there was a reversal in the disease
decline, as the patients had gained a mean of 11.4% of their
strength (P=0.001), reaching almost the level of strength they
had exhibited 12-18 months earlier (Fig. 2).
Functional signiﬁcance of increased
strength in the improved patients
The noted strength changes were of functional importance to
the daily activities of some of the patients when asked to judge
the clinical signiﬁcance of their beneﬁt. Five patients reported
absolutely no beneﬁt, three experienced a moderate but clear
effect; and ﬁve had a deﬁnite improvement, requesting another
infusion. The improved patients experienced the beneﬁt 2 months
after treatment, for up to 5–8 months and reported an increased
ability to perform the following: walk further distances with better
balance and less falls; get up from a chair; step up into the car or
go up steps; button shirts or use utensils; and lift heavier objects
(one patient who was exercising regularly, became able to lift
more weights and increased his repetitions).
Figure 1 Changes in muscle strength using QMT. During a
12-month natural history period there is a decline in muscle
strength based on QMT measurements by a mean of 14.9%.
After 6 months of CAMPATH treatment the mean total muscle
strength scores changed by a 1.9% from baseline (P=0.002).
At month 12 from CAMPATH initiation (6 months of follow-up
without therapy), the patients’ strength had declined by a
mean of 9.7% (P50.01) reaching almost the baseline.
Figure 2 Total muscle strength scores obtained with MRC
measurements before and after CAMPATH. A mean of 13.8%
decline was noted during a 24-month natural history period
and 9.1% decline during a 12-month period. Six months after
CAMPATH, the total strength improved be a mean of 11.4%
(P=0.0001) reaching almost the level of strength the patients
had 2.5 years earlier.
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blood lymphocytes and muscle
Peripheral blood lymphocytes of all phenotypes were markedly
reduced immediately after treatment. Repopulation began slowly
thereafter and by the 6th month (the study’s primary efﬁcacy
endpoint and the time a repeated muscle biopsy was performed)
the ALC was 30% of the baseline level; by month 12, the ALC
had reached the 50% level (Table 1 and Fig. 3A). Depletion
occurred, and repopulation proceeded, in an inhomogeneous
fashion with respect to the surface phenotype for both CD4
and CD8+ T cells. As reported (Pearl et al., 2005), naı ¨ve cells
were more effectively depleted compared to antigen-experienced
cells, particularly those of the effector memory subset (Table 2
and Fig. 3B for the kinetics of a representative patient). The
peripheral population became predominantly memory phenotype
and remained largely comprised of effector and central memory
cells throughout the study period, although some regeneration of
naı ¨ve cells was evident within 3 months and later thereafter
(Table 2 and Fig. 3B).
In the repeated biopsies, there was an overall reduction in the
lymphocytes and an improvement in the muscle cytoarchitecture.
Quantiﬁcation of the lymphocytes, in all biopsies before and after
CAMPATH, demonstrated a signiﬁcant decline in the total number
of CD3+ cells (P=0.008; Fig. 4A). This was in contrast to the
mean number of endomysial lymphocytes during the 12-month
natural history period that had increased, from 708350 to
907313 (Fig. 4B). In four of the ﬁve patients who improved,
the repeated muscle biopsies showed a 450% depletion of the
CD3+ T cells. The reduction of endomysial T cells and improved
muscle cytoarchitecture are depicted in the samples of two
representative patients before and after therapy (Fig. 5A–B).
Figure 3 Changes in peripheral blood lymphocytes after CAMPATH. (A) A reduction of total peripheral blood lymphocytes
immediately after CAMPATH was noted with a steady repopulation (occurring slowly up to 12 months) in all patients. (B) The
kinetics of CD8 + T cells subsets after CAMPATH, including changes in the memory T cells, is shown for a representative patient.
A depletion of naı ¨ve CD4+ and CD8+ T cells, compared to effector memory cells, was noted in nine patients (shown in Table 2).
Table 1 Absolute lymphocyte count in the peripheral blood before and 12 months after CAMPATH
Patient # Baseline Post-Campath 1 month 3 months 6 months 8 months 10 months 12 months
1 1.897 0.012 0.08 0.248 0.271 0.433 0.693 0.705
2 1.285 0.058 0.213 0.349 0.661 0.595 0.798 0.867
3 1.206 0.071 0.564 0.688 0.938 0.729 1.067 1.183
4 1.528 0.026 0.101 0.39 0.458 0.456 0.369 0.653
5 1.341 0.004 0.145 0.178 0.339 0.442 0.358 0.617
6 2.933 0.062 0.268 0.412 0.621 1.658 2.118 2.284
7 1.132 0.033 0.381 0.543 0.59 0.685 0.519 0.599
8 2.323 0.03 0.187 0.591 0.706 0.76 0.8 1.005
9 2.532 0 0.097 0.29 1.126 1.115 1.072 1.308
10 1.622 0 0.053 0.383 0.379 0.534 0.666 0.724
11 2.076 0 0.231 0.381 0.46 0.621 0.799 0.882
12 1.612 0 0.059 0.563 0.607 0.725 0.936 1.043
13 2.576 0 0.032 0.351 0.407 1.049 1.284 1.352
Mean 1.851 0.02 0.185 0.412 0.581 0.754 0.883 1.017
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T cells (A). In contrast, during the natural history period prior to CAMPATH, the total lymphocyte count had remained unchanged
or increased (B).
Figure 5 (A) Representative muscle biopsy samples performed before and 6 months after treatment (stained with H&E) demonstrate
reduction of lymphocytic inﬁltrates. With immunocytochemistry (B), a reduction of CD3- and CD8-positive lymphocytes was noted.
Table 2 Longitudinal changes (SD) up to 6 months from baseline, in the percentage of naı ¨ve and memory T cells in
nine patients treated with CAMPATH
Base 1 Month 3 Months 6 Months
CD4
Naı ¨ve (CD45RA
+ CD62L
+) 23.714.7 0.91.8 8.28.7 7.69.4
Central memory (CD45RA
 Cd62
+) 44.412.9 46.026.1 45.414.4 47.613.7
Effector memory (CD45RA
 CD62
) 28.117.6 37.123.4 45.317 43.416.3
RA+ effector memory (CD45RA
+ CD62
) 4.54.8 6.213.3 7.417.1 3.35.4
CD8
Naı ¨ve (CD45RA
+ CD62L
+) 26.817.4 0.91.6 8.212.3 7.627.4
Central memory (CD45RA
 Cd62
+) 14.714.2 17.628 10.38.8 174.3
Effector memory (CD45RA
 CD62
) 29.614.8 36.820 46.421 37.923
RA
+ Effector memory (CD45RA
+ CD62
) 28.923.9 31.624.2 34.625.1 24.315.4
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expression of inﬂammatory mediators
and degeneration-associated molecules
in the repeated muscle biopsies
The mRNA of Fas, Mip-1a, and aB crystallin associated with
degeneration or cell stress of myoﬁbres, was signiﬁcantly reduced
after treatment both at the mRNA and protein level (Fig. 6B).
In contrast, the mRNA of desmin, associated with regeneration,
was statistically increased after treatment (Fig. 6A). No signiﬁ-
cant changes were noted in the mRNA expression for ILb, IL-6,
CD28, CD40, CD52, CD86, CD15, Granzyme B, MCP-1, Mip-3b,
mig, MMP-2 and MMP-9, APP and ubiquitin. Protein expression
of the chemokine CXCL-9 was clearly reduced in some patients
as indicated by the double immunohistochemical staining for
CXCL9 and CD8 (Fig. 6C).
Safety and tolerance
The drug was well tolerated. No secondary infections, thyroiditis
or idiopathic thrombocytopenic purpura (ITP) were observed up to
2 years after treatment. Infusion-related events were observed in
three patients manifested as transient hypotension. The only com-
plication—not directly related to the drug—was thrombosis of the
subclavian vein in one patient caused by the PIC line.
Discussion
This proof-of-principle study showed that a long-lasting reduction
of peripheral T cells, as caused by CAMPATH, results in reduction
of endomysial T cells and has the potential to arrest disease pro-
gression or improve strength of some patients with inclusion-body
myositis (IBM). The study, designed to capture changes in the
natural history of IBM, supports the view that aggressive immuno-
therapy may slowdown the course of the disease, at least for some
patients, and opens the opportunity to explore long-term beneﬁts
with follow-up infusions.
In spite of the association of IBM with other autoimmune
disorders and viruses and the prominent clonal expansion of endo-
mysial cytotoxic T cells (Koffman et al., 1998; Muntzing et al., 2003;
Badrising et al., 2004; Dalakas, 2006; Salajegheh et al., 2007;
Chanin and Engel, 2008), conventional immunotherapies, including
IVIg (Dalakas et al., 1997, 2001), have failed to provide signiﬁcant
beneﬁts. The resistance of IBM to most immunotherapies has
generated dilemmas about its pathogenesis, prompting the sugges-
tion that it might be a primary neurodegenerative disorder (Askanas
and Engel, 2006). The present study, powered to detect a 410%
change in strength, demonstrated improvement in some patient’s
strength and a slowdown in the overall disease progression based on
the natural history data, for up to 6 months. Although the study
was unblinded, the results are unbiased because: (i) the evaluators
Figure 6 Quantitative mRNA expression of desmin (A) and aB crystalline (B) in the patients’ repeated muscle biopsies before and
6 months after CAMPATH. There is a signiﬁcant increase of desmin and reduction of aB-crystallin. A signiﬁcant decline of mRNA
expression of Mip-1a (CCL-3) was also noted (not shown); at the protein level, CXCL9 was reduced in some patients, as observed
in double immunohistochemical staining for CXCL-9 and CD8 (C).
P50.05;
P50.01.
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day-to-day activity of the patients; (ii) the data were obtained simul-
taneously with the other patients participating in the natural his-
tory study that involved a large cohort of IBM patients; (iii) the
QMT data were collected by the same evaluators who had per-
formed the natural history study in the same patients; (iv) the
MRC measurements, which usually display less variability than
the QMT scales, independently provided convincing support for a
more prominent stability or improvement; (v) IBM has not improved
with any intervention in a 6-month period and, as shown from the
natural history, it has a steady decline; and (vi) the gains in strength
lasted 6 months, coinciding with the effect of CAMPATH on T cell
depletion, reverting thereafter almost to baseline level. Most impor-
tantly, the noted strength changes in the improved patients were
meaningful to their daily activities, although some placebo effect
cannot be excluded.
The study was designed to examine the relationship between
T lymphocyte depletion and clinical response up to 6 months after
treatment. It appears that the duration of the beneﬁcial effect
correlated with the re-emergence of peripheral CD8+ Memory
T cells. Although the naı ¨ve T cells remained suppressed after
6 months, the memory T cells were less affected and may be
responsible for the persistent inﬂammatory response in some
patients. Follow-up infusions therefore, after 4–6 months, may
be needed to sustain or enhance the clinical beneﬁt, as commonly
applied to other autoimmune diseases. The incomplete elimination
of antigen-experienced cells may have accounted for the lack of
clinical response in some of the patients but it might have
contributed to the overall good safety proﬁle of the applied
intervention. CAMPATH was also effective in reducing the endo-
mysial T cells, as determined from the repeated biopsies. Although
there may be some variability in the degree of inﬂammation
from muscle-to-muscle, our data are consistent with a drug-
related reduction because: (i) the same muscle was biopsied
twice; (ii) the assessment was based on counting the mean
number of endomysial lymphocytes in a large number of biopsies;
and (iii) the reduction was signiﬁcant when compared to the nat-
ural history biopsies performed on the same patients’ opposite arm
12–18 months before CAMPATH. The observation, that the most
prominent T cell reduction was observed in the muscles of those
ﬁve patients who had the most notable clinical beneﬁt, suggests
that in IBM the T cells are related to the immunopathogenesis
of the disease and play a central role in tissue destruction. The
concomitant improvement in the histopathology along with the
downregulation of the cell-stressor molecule aB crystallin, pre-
viously noted to be enhanced in sIBM muscles (Banwell and
Engel, 2005; Schmidt et al., 2008), supports the view that in
IBM the T cell-mediated cytotoxicity is involved in inducing cell-
stress to the myoﬁbres (Nagaraju et al., 2005; Dalakas, 2006).
Inclusion-body myositis remains a complex disorder and immune
mechanisms may not be the only culprit in the disease mecha-
nisms. Whether the vacuolar degeneration is a consequence of the
chronic inﬂammation related to the long-lasting cytokine upregu-
lation and the MHC-I-induced cell stress, as proposed (Nagaraju
et al., 2005; Dalakas, 2006), or it is an independent factor,
remains unclear. Although a direct interrelationship between
inﬂammation and degeneration has been demonstrated in sIBM
muscles (Nagaraju et al., 2005; Schmidt et al., 2008), we could
not ﬁnd any signiﬁcant changes in the correlation between the
degeneration-associated molecules, such as b-amyloid or ubiquitin,
with inﬂammatory mediators in the repeated biopsies, probably
because the period of therapy was too short to capture any appre-
ciable change at the mRNA level. IBM is a chronic disease and any
effect on degeneration markers may require long-term therapy.
The drug, as given, was well tolerated without any immediate
or long-term side-effects, such as thyroiditis or ITP, as reported in
other trials (the CAMMS233 Trial, 2008). Although the sample
was small, it was powered to capture changes in muscle strength
even in a 6-month period owing to the availability of natural
history data in the same patients. Even if the improvement was
arguably modest, no other agent has shown any similar effect in
the decline of the disease course. Some beneﬁts noted with IVIg
or with anti-thymocyte globulin were marginal and short-lived
(Dalakas et al., 1997; Lindberg et al., 2003). Because IBM is pre-
dictably disabling and notoriously resistant to therapies, the
encouraging results from this pilot study and the good tolerance
of the drug, provide the impetus to consider a large placebo-
controlled trial with repeated infusions to assess the long-term
beneﬁts keeping in mind the safety concerns raised in the recent
multiple sclerosis trial (the CAMMS233 Trial, 2008).
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